Phathom Pharmaceuticals Inc

Phathom Pharmaceuticals is a commercial-stage biopharmaceutical company focused on treatments for gastrointestinal diseases. It holds exclusive in-licensed rights from Takeda to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), for the U.S., Europe and Canada. In the United States it markets vonoprazan as VOQUEZNA tablets, approved for:
- relief of heartburn associated with Non-Erosive GERD in adults;
- healing and maintenance of healing of Erosive GERD in adults, and relief of associated heartburn;
- H. pylori infection in adults, as part of VOQUEZNA DUAL PAK and VOQUEZNA TRIPLE PAK.

Revenue comes from net product sales of VOQUEZNA through covered (insured) and cash-pay channels, including a pharmacy partnership with BlinkRx. The company is pursuing label expansion through a Phase 3 program for as-needed use in Non-Erosive GERD and a Phase 2 trial in eosinophilic esophagitis. It is financed in part through a term loan and a revenue interest financing agreement. It is defending VOQUEZNA's NCE regulatory exclusivity, which it says runs through May 2032, in litigation brought by BDR Pharmaceuticals against the FDA. Updated Oct 29, 2026